<DOC>
	<DOCNO>NCT01839357</DOCNO>
	<brief_summary>A study subject atrial fibrillation ( AF ) atrial flutter diagnose leave atrial ( LA ) leave atrial appendage ( LAA ) thrombus . The study assign subject rivaroxaban treatment thrombus . The study measure thrombus outcome base echo image common clinical outcome bleed stroke thromboembolism .</brief_summary>
	<brief_title>Exploring Efficacy Once Daily Oral Rivaroxaban Treatment Thrombus Left Atrial/Left Atrial Appendage Subjects With Nonvalvular Atrial Fibrillation Atrial Flutter</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Men woman age &gt; /= 18 year Hemodynamically stable nonvalvular AF atrial flutter LA/LAA thrombus document baseline transesophageal echocardiography ( TEE ) 72 hour prior start study medication vitamin K antagonist ( ) ( VKA ) / new oral anticoagulant ( ) ( NOAC ) naïve untreated within 1 month prior sign inform consent form VKA pretreated ineffective INR level ( &lt; 2.0 , document least 2 consecutive measurement least 24 hour apart ) within last 6 week Women childbearing potential men must agree use adequate contraception sexually active Transient Ischemic Attack within 3 day prior study inclusion Severe , disable stroke ( modify Rankin score 45 , inclusive ) within 3 month stroke within 14 day start study drug Acute thromboembolic event thrombosis ( venous/arterial ) within last 14 day prior study inclusion Acute myocardial infarction within last 14 day prior study inclusion Cardiacrelated criterion : Previous intracardiac thrombus , Freefloating ball thrombus , Intracardiac tumor , know leave ventricular aortic thrombus Active bleeding high risk bleed contraindicate anticoagulant therapy Concomitant drugs/therapies : Indication anticoagulant therapy condition nonvalvular AF atrial flutter ( eg , venous thromboembolism ) . Concomitant use anticoagulant drug , include VKA , factor IIa factor Xa inhibitor . Chronic aspirin therapy &gt; 100 mg dual antiplatelet therapy . Concomitant use strong inhibitor cytochrome P450 ( CYP ) 3A4 P glycoprotein ( Pgp ) , ie , human immunodeficiency virus protease inhibitor follow azole antimycotic agents—ketoconazole , itraconazole , voriconazole , posaconazole—if use systemically Concomitant condition : Childbearing potential without proper contraceptive measure , pregnancy , breast feeding . Hypersensitivity investigational treatment . Calculated creatinine clearance ( CrCl ) &lt; 15 mL/minute screen visit . Hepatic disease associate coagulopathy lead clinically relevant bleeding risk . Any severe condition would limit life expectancy le 3 month ( eg , advanced malignancy , etc. ) . Planned invasive procedure potential uncontrolled bleeding increase risk stroke , include major surgery , cardiac catheterization , cardioversion prior endoftreatment TEE . Inability take oral medication . Ongoing drug addiction alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Rivaroxaban</keyword>
	<keyword>Oral anticoagulant</keyword>
	<keyword>Nonvalvular atrial fibrillation</keyword>
	<keyword>Left atrial thrombus</keyword>
	<keyword>Transesophageal echocardiography</keyword>
	<keyword>Thrombus resolution</keyword>
	<keyword>Stroke</keyword>
	<keyword>Thromboembolism</keyword>
</DOC>